Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma

Liu, Wei; Wang, Kun; Bao, Quan; Sun, Yi; Xing, Baocai

doi:10.1186/s12957-016-0811-y

Cited by 43 publications

(29 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the authors concluded that the efficacy of hepatic resection is superior than cTACE. This finding was also supported by a retrospective non-randomized-controlled trial by Biao Yang et al [21][22][23][24] . who showed that hepatic resection provides significantly higher survival benefits to resectable HCC patients than TACE.…”

Section: Discussionsupporting

confidence: 65%

Hepatic resection versus TILA-TACE in the treatment of Resectable Hepatocellular Carcinoma: study protocol for a randomized controlled trial

Feng

Jin

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Hepatic resection and transcatheter arterial chemoembolization (TACE) are common treatments for hepatocellular carcinoma (HCC). Targeting intratumoral lactic acidosis TACE (TILA-TACE) is a new therapeutic approach developed by our team that has superior response rate and effective rate than conventional TACE (cTACE). In this randomized-controlled trial, we will compare the efficacy of hepatic resection and TILA-TACE in patients clinically diagnosed with HCC to provide reliable clinical data for the subsequent effective treatment of HCC patients. Methods: A total of 230 resectable HCC patients will be given hepatic resection or TILA-TACE using a parallel-controlled approach, and the efficacy of the treatments Page 4 of 24 will be compared. The primary endpoint is the post-treatment progression-free survival (PFS) of the patients, and the secondary endpoints are the post-treatment overall survival (OS), 1-year, 3-year and 5-year survival, and the quality of life of the patients at each corresponding stage. Discussion: The aim of this study is to compare the efficacy of hepatic resection and TILA-TACE in the treatment of resectable HCC. Trial registration: ClinicalTrials.gov,NCT03314532.Registered on 19 October 2017. Keywords: Hepatocellular carcinoma, Hepatic resection, TACE, TILA-TACE, Randomized-controlled study.

show abstract

Section: Discussionsupporting

confidence: 65%

Hepatic resection versus TILA-TACE in the treatment of Resectable Hepatocellular Carcinoma: study protocol for a randomized controlled trial

Feng

Jin

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Some of pathological factors are often taken as an important risk factor for the HCCR (29,30). In our series, cancerous infiltration of the capsule was also accounted as an independent risk factor for HCCR.…”

Section: Multivariate Analysissupporting

confidence: 51%

Risk Factors for Recurrence of Hepatocellular Carcinoma after Curative Resection

Shimoda¹,

Maruyama²,

Suzuki³

et al. 2018

SGO

View full text Add to dashboard Cite

Background/Aims: Hepatic surgical resection is one of the most effective treatment for hepatocellular carcinoma (HCC). However, recurrence of HCC (HCCR) is still very common among operated patients, and its risk factors still remains unclear. Materials and Methods: We have conducted a retrospective study of 56 patients operated for HCC in our medical center during April 2008 through March 2016, to analyze the risk factors for HCCR. The ideal cutoff values of laboratory parameters was defined using the Receiver Operating Characteristic (ROC) curve analysis, and logistic regression model analyses were used to calculate odds ratios with 95% CI. P values less than 0.05 were considered as statistically significant. Results and Conclusion: All 56 patients accrued to this retrospective study underwent curative resection of HCC. The patients compromised of 11 female and 45 male, with the median age of 68.5years. Twenty-three out of 56 (40.1%) patients experienced HCC recurrence, and the Median time of recurrence was 14.5 months.The 5-year cancer-free survival rate was 42.5%. Univariate analysis showed that the use of intermittent Pringle Maneuver (IPM: p=0.036), limited resection (LR: p=0.011), and cancerous infiltration of the capsule (fc-inf; p=0.017), were associated with HCC recurrence. According to the multivariate analysis, using IPM (p=0.008), LR (p=0.012), and fc-inf (p=0.014), were risk factors for patients with HCCR.

show abstract

“…Surgery is potentially curative for patients with limited sites of malignant disease, particularly those in the early stage (28)(29)(30)(31). FDG-PET/CT is helpful in the selection of patients who might derive significant survival benefits from optimal surgical strategies.…”

Section: Discussionmentioning

confidence: 99%

Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

Chan

Liu

Liou

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: Whole-body positron-emission tomography/computed tomography with the glucose analog 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG-PET/CT) has been used to screen examinees for underlying malignancy in many countries. The aim of this study was to compare the potential value of FDG-PET/CT application in asymptomatic individuals with those with suspected malignancy. Patients and Methods: A total of 9,408 examinees underwent wholebody FDG-PET/CT at our hospital from July 2006 to August 2013. Three thousand and seven hundred asymptomatic individuals and 848 individuals with laboratory and clinical/radiologicaI suspicion of malignancy who had undergone FDG-PET/CT for cancer screening were recruited. The final confirmation of cancer and outcomes were based on a pathological report and continuous followup. Results: Forty-five out of 3,700 asymptomatic individuals (1.2%) had proven malignancy, and 42 of them (93.3%) were found by FDG-PET/CT. Two hundred and twelve out of 848 with suspected malignancy (25%) had proven malignancy, and 196 of them (92.5%) were detected by FDG-PET/CT. Most of these cancers in asymptomatic individuals were clinically at an early stage. The discovery rate in asymptomatic individuals and those with suspected malignancy was 1.1% and 23.1%, respectively. The overall survival of patients with cancer diagnosed with PET/CT was higher than those with suspected malignancy (78.6% vs.

show abstract

Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma

Cited by 43 publications

References 49 publications

Hepatic resection versus TILA-TACE in the treatment of Resectable Hepatocellular Carcinoma: study protocol for a randomized controlled trial

Hepatic resection versus TILA-TACE in the treatment of Resectable Hepatocellular Carcinoma: study protocol for a randomized controlled trial

Risk Factors for Recurrence of Hepatocellular Carcinoma after Curative Resection

Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

Contact Info

Product

Resources

About